Testing for lupus anticoagulants: All that a clinician should know

Lupus

Volumn 18, Issue 4, 2009, Pages 291-298

  Tripodi, Amando ^a,b  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b NONE   (Italy)

Author keywords

Antiphospholipid syndrome; Foetal loss; Laboratory testing; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 10; CARDIOLIPIN ANTIBODY; CLOPIDOGREL; HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; THROMBIN; THROMBIN INHIBITOR;

ANTIBODY DETECTION; ANTIBODY TITER; ANTIPHOSPHOLIPID SYNDROME; BLOOD ANALYSIS; BLOOD CLOTTING TIME; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REFERENCE VALUE; REVIEW; STANDARDIZATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; DIAGNOSIS, DIFFERENTIAL; HEMATOLOGIC TESTS; HISTORY, 20TH CENTURY; HUMANS; LUPUS COAGULATION INHIBITOR;

EID: 62749176416     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203308101436     Document Type: Review

References (36)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
3. Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952; 31: 621-622.
4. Bowie EJ, Thompson Jr JH, Pascuzzi CA, Owen Jr CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med 1963; 62: 416-430.
5. Tripodi A, Biasiolo A, Chantarangkul V, Pengo V. Lupus anticoagulant (LA) testing: Performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem 2003; 49: 1608-1614.
6. Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russell viper venom time for the diagnosis of lupus anticoagulants. Blood 1986; 68: 869-874.
7. Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell viper venom time distinguish between prothrombindependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86: 617-623.
8. Pengo V, Biasiolo A, Rampazzo P, Brocco T. dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-beta2-glycoprotein I autoantibodies. Thromb Haemost 1999; 81: 256-258.
9. de Laat HB, Derksen RH, Urbanus RT, Roest M, de Groot PG. beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004; 104: 3598-3602.
10. Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost 1987; 57: 144-147.
11. Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993; 70: 787-793.
12. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: Results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost 1995; 74: 1597-1603.
13. Tripodi A, Mancuso ME, Chantarangkul V, et al. Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. Clin Chem 2005; 51: 1883-1885.
14. Chantarangkul V, Tripodi A, Arbini A, Mannucci PM. Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. Thromb Res 1992; 67: 355-365.
15. Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA,Wisloff F. The Lupus Ratio test; an interlaboratory study on the detection of Lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test. Fifth International Survey of Lupus Anticoagulants ISLA 5. Thromb Haemost 2000; 83: 704-708.
16. Tripodi A, Chantarangkul V, Clerici M, Mannucci PM. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost 2002; 88: 583-586.
17. Triplett DA, Stocker KF,Unger GA, Barna LK. The Textarin/Ecarin ratio: A confirmatory test for lupus anticoagulants. Thromb Haemost 1993; 70: 925-931.
18. Moore GW. Combining Taipan snake venom time/Ecarin time screening with the mixing studies of conventional assays increases detection rates of lupus anticoagulants in orally anticoagulated patients. Thromb J 2007; 5: 12.
19. Feinstein DI. Acquired disorders of hemostasis. In: Colman RW, Hirsh J,Marder VJ, Salzman EW, (eds), Hemostasis and thrombosis. Basic principles and clinical practice. 3rd ed. Philadelphia: Lippincott; 1994. p. 881-905.
20. Sletnes KE, Gravem K, Wisloff F. Preparation of plasma for the detection of lupus anticoagulants and antiphospholipid antibodies. Thromb Res 1992; 66: 43-53.
21. Chantarangkul V, Tripodi A, Clerici M, Bressi C, Mannucci PM. Laboratory diagnosis of lupus anticoagulants; effect of residual platelets in plasma, assessed by Staclot LA and silica clotting time. Thromb Haemost 2002; 87: 854-858.
22. Le Querrec A, Arnout J, Arnoux D, et al. Quantification of lupus anticoagulants in clinical samples using anti-beta2GP1 and antiprothrombin monoclonal antibodies. Thromb Haemost 2001; 86: 584-589.
23. Galli M, Comfurius P, Barbui T, Zwaal RF, Bevers EM. Anticoagulant activity of beta 2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 1992; 68: 297-300.
24. Simmelink MJ, Derksen RH, Arnout J, De Groot PG. A simple method to discriminate between beta2-glycoprotein I- and prothrombin-dependent lupus anticoagulants. J Thromb Haemost 2003; 1: 740-747.
25. Pengo V, Biasiolo A, Pegoraro C, Iliceto S. A two-step coagulation test to identify antibeta-glycoprotein I lupus anticoagulants. J Thromb Haemost 2004; 2: 702-707.
26. Jennings I, Kitchen S, Woods TA, Preston FE, Greaves M. Potentially clinically important inaccuracies in testing for the lupus anticoagulant: An analysis of results from three surveys of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost 1997; 77: 934-937.
27. Brandt JT, Triplett DA, Rock WA, Bovill EG, Arkin CF. Effect of lupus anticoagulants on the activated partial thromboplastin time. Results of the College of American Pathologists survey program. Arch Pathol Lab Med 1991; 115: 109-114.
28. Roussi J, Roisin JP, Goguel A. Lupus anticoagulants. First French interlaboratory Etalonorm survey. Am J Clin Pathol 1996; 105: 788-793.
29. Favaloro EJ, Bonar R, Sioufi J, et al. Multilaboratory testing of thrombophilia: Current and past practice in Australasia as assessed through the royal college of pathologists of the Australasia quality assurance programs for hematology. Semin Thromb Haemost 2005; 49-58.
30. Favaloro EJ, Bonar R, Duncan E, et al. (on behalf of the RCPA QAP in Haematology Haemostasis Committee). Identification of factor inhibitors by diagnostic haemostasis laboratories: A large multicenter evaluation. Thromb Haemost 2006; 96: 73-78.
31. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Thromb Haemost 1999; 81: 929-934.
32. Pengo V, Biasiolo A, Gresele P, et al. on behalf of participating centers of Italian Federation of Thrombosis Centers (FCSA). Survey on lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 2007; 5: 928-930
33. Esmon NL, Smirnov MD, Esmon CT. Thrombogenic mechanisms of antiphospholipid antibodies. Thromb Haemost 1997; 78: 79-82 [Review].
34. Galli M, Ruggeri L, Barbui T. Differential effects of antibeta2-glycoprotein I and ntiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998; 91: 1999-2004.
35. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TA, Preston FE. UK National External Quality Assessment Scheme for Blood Coagulation. Lupus anticoagulant testing: Improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol 2002; 119: 364-369.
36. Pengo V, Biasiolo A, Gresele P, et al. A comparison of Lupus Anticoagulant positive patients with classical picture of Antiphospholipid Syndrome and those without. Arterioscler Thromb Vasc Biol 2007; 27: 309-310.